| Document |
Document Title |
|
WO/2023/199241A1 |
It is an object of the present invention a composition comprising lipoic acid, or a pharmaceutically or food grade acceptable salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, and glutathione...
|
|
WO/2023/199908A1 |
The present disclosure addresses the problem of providing at least a technique for producing a composition in which urolithins are solubilized. The problem is solved by a method for producing an emulsified composition, the method compris...
|
|
WO/2023/197914A1 |
Provided is novel use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof in preventing or treating hypersensitivity or an autoimmune inflammation-related disorder.
|
|
WO/2023/197484A1 |
The present invention provides use of aristolochic acid IVa in preparing antihistamines or drugs for treating pneumonia, wherein aristolochic acid IVa and a pharmaceutically acceptable salt thereof are used as active ingredients. In one ...
|
|
WO/2023/198873A1 |
The application relates to isoxazolyl-pyrazole derivatives of the general formula (I) for the treatment of diseases and conditions such as psoriasis, autoimmune thyroiditis, inflammatory bowel disease and cancer in which inverse agonism ...
|
|
WO/2023/198704A1 |
The present invention provides a two-component drug delivery system for intravenous administration of an aqueous and sterile acetylsalicylic acid composition comprising: a first and second component which are physically separated, wherei...
|
|
WO/2023/198294A1 |
The invention provides a two-component drug delivery system for intravenous administration of an aqueous sterile acetylsalicylic acid composition comprising: a first and second components physically separated. The first component compris...
|
|
WO/2023/200210A1 |
The present invention relates to a pharmaceutical composition for treating inflammatory bowel diseases, comprising an arylethene derivative as an active ingredient. By using the present invention, inflammatory bowel diseases can be effec...
|
|
WO/2023/198833A1 |
The current invention relates to a compound or a pharmaceutical composition comprising a therapeutically effective amount of said compound for use in the treatment of a disease, disorder or condition responsive to the inhibition of the N...
|
|
WO/2023/201371A1 |
The present disclosure provides composition and methods preparing a population of isolated MSCs for pharmaceutical application, the method comprising: providing a population of isolated MSCs; and synchronizing the population of isolated ...
|
|
WO/2023/200258A1 |
The present invention provides: a method for differentiating pluripotent stem cells into mesenchymal stem cells in the presence of a BMP4 signaling agonist; mesenchymal stem cells obtained thereby; and extracellular vesicles obtained fro...
|
|
WO/2023/199244A1 |
It is an object of the present invention a composition comprising N-acetylcysteine, or a pharmaceutically or food grade acceptable salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, and prefer...
|
|
WO/2023/151653A9 |
An oleogel and a preparation method therefor and a use thereof. The oleogel comprises 60-90 wt% of liquid oil, 6-35 wt% of a structuring agent, and 4-15 wt% of water. The liquid oil comprises an unsaturated fatty acid, and the structurin...
|
|
WO/2023/197466A1 |
An aspergillus cristatus spore polysaccharide, and a preparation method therefor and an application thereof. The preparation method comprises: performing wall-breaking on aspergillus cristatus spores, then performing drying, grinding int...
|
|
WO/2023/201247A1 |
The present inventive concept provides methods for reducing, treating and/or managing inflammation across a wide range of states associated with injury, disease, and/or aging; reducing or inhibiting disease progression and fibrosis, and ...
|
|
WO/2023/196876A1 |
IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are disclosed. The IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are IL-7R agonists.
|
|
WO/2023/196838A1 |
The present disclosure relates to the use of an anti‑IL6 receptor antibody, or an antigen‑binding fragment thereof, for treating polymyalgia rheumatica (PMR).
|
|
WO/2023/196866A1 |
In some aspects, provided herein are antibodies or antigen-binding fragments that bind to CD200R, a glycoprotein receptor present on cell surfaces. Antibodies or antigen-binding fragments provided herein, in some cases, agonize CD200R si...
|
|
WO/2023/195809A1 |
The present invention relates to a novel compound having histone deacetylase 6 (HDAC6) inhibitory activity, a method for preparing the same, and uses thereof. The novel compound according to the present invention, a stereoisomer thereof ...
|
|
WO/2023/195834A1 |
The present invention relates to a pharmaceutical composition for treating neuropathic pain, the composition comprising, as an active ingredient, an epitope of a macrophage-inducible C-type lectin (Mincle) protein, wherein the epitope co...
|
|
WO/2023/196975A1 |
Provided herein are compounds of Formula (I), or a pharmaceutically acceptable form thereof, and pharmaceutical compositions comprising the same. Also provided herein methods of modulating the activity of cellular targets by administerin...
|
|
WO/2023/195527A1 |
The purpose of the present invention is to increase the amount of oligo-nucleic acid transported into a cytoplasm by bringing about an efficient interaction of a cell uptake promoter with a target cell. An oligo-nucleic acid nanoparticle...
|
|
WO/2023/195669A1 |
The present invention relates to a novel benzothiophene derivative and use thereof as a bromodomain extra-terminal (BET) inhibitor, and, more specifically, to a novel benzothiophene derivative compound of the following chemical formula 1...
|
|
WO/2023/196532A1 |
Described herein are methods for treating pouchitis by orally administering a cholix-IL-10 fusion protein. Corresponding oral formulations and the effects resulting from administration of such oral formulations are disclosed.
|
|
WO/2023/196432A1 |
Disclosed herein, inter alia, are compounds of formula (I) and methods of use thereof for the modulation of certain chemokine receptor activity.
|
|
WO/2023/193341A1 |
Provided are a sphingolipid compound shown in formula (I), a liposome containing the sphingolipid compound, and an application. The sphingolipid compound is prepared by taking a long-chain alkyl group as a hydrophobic tail part, and bond...
|
|
WO/2023/185931A1 |
The present invention relates to a P2X3 inhibitor compound, a salt thereof, a polymorph thereof and use thereof. The present invention provides a crystalline form of a compound of formula I, which has good medicinal properties. A pharmac...
|
|
WO/2023/191310A1 |
The present invention relates to a composition for improving antioxidant, anti-aging, antibacterial, anti-inflammatory, or cognitive function. More specifically, the composition comprises a solid-phase fermented Schizandra chinensis Bail...
|
|
WO/2023/192361A1 |
Methods of treating a subject for fibromyalgia are provided. Aspects of the methods include administering to the subject a tropane CCR5/CCL5 interaction inhibitor, either alone or in combination with a statin, to treat the subject for fi...
|
|
WO/2023/186102A1 |
The present invention provides a Nav1.8 inhibitor. Particularly, the present invention provides a compound represented by formula I, or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug the...
|
|
WO/2023/192960A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.
|
|
WO/2023/191530A1 |
The present invention relates to a composition for the prevention, alleviation, or treatment of inflammatory diseases, allergic diseases, or sepsis. A composition according to one aspect inhibits the expression or activity of the preinfl...
|
|
WO/2023/186072A1 |
The present disclosure relates to a ligand-drug conjugate of a novel structure or a pharmaceutically acceptable salt thereof. Specifically, the present disclosure provides a ligand-drug conjugate of a structural general formula of Pc-(L-...
|
|
WO/2023/187707A1 |
A method of treating mild to moderate psoriasis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of th...
|
|
WO/2023/185448A1 |
The present invention relates to the technical field of medicines, and in particular, to a use of methyl gallate in the preparation of drugs for treating osteoarthritis. Methyl gallate can relieve the injury of chondrocytes, ameliorate o...
|
|
WO/2023/185869A1 |
The present disclosure relates to a crystalline form of a fumarate of a pyrroloheterocyclic derivative and a preparation method therefor. Specifically, the present disclosure relates to a crystalline form V of a fumarate of a compound re...
|
|
WO/2023/187205A1 |
The present invention concerns a Parabacteroides distasonis strain deposited under accession number CNCM I-5828. This strain can be useful in multiple applications, in particular incorporated in a nutritional supplement or in a compositi...
|
|
WO/2023/188931A1 |
One composite composition according to the present invention contains silicon fine particles having an average particle size greater than 1 μm and less than 45 μm and/or aggregates of the silicon fine particles and comprises silicon ox...
|
|
WO/2023/190465A1 |
Provided is a functional human anti-SEMA7A antibody. This invention relates to an anti-SEMA7A antibody in human having a specific CDR sequence, or an antibody fragment of this antibody.
|
|
WO/2023/192351A1 |
Described herein are methods and compositions for treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a ...
|
|
WO/2023/114832A9 |
The disclosure relates to stable topical pharmaceutical compositions of SHR0302 (also known as ARQ-250). In certain embodiments, pharmaceutical compositions of SHR0302 having a pH of less than about 4.6 have improved stability and do not...
|
|
WO/2023/192388A1 |
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (...
|
|
WO/2023/191531A1 |
The present invention relates to a composition for preventing, ameliorating, or treating inflammatory diseases, allergic diseases, or sepsis. As a composition that inhibits the expression or activity of pro-inflammatory cytokines IL-8 or...
|
|
WO/2023/191997A1 |
Compositions and methods are provided that mitigate iron imbalance resulting from inflammation and/or mitigate the effects of inflammatory disease. This can be accomplished by correcting dysregulation of iron internalization. Such correc...
|
|
WO/2023/191003A1 |
The purpose of the present disclosure is to provide a novel dental preparation used in treating tissue defects. The dental preparation contains a molded material obtained by drying a raw material aqueous solution containing (A) collage...
|
|
WO/2023/185667A1 |
The present invention provides an HDAC11 subtype selective inhibitor, and a preparation method therefor and use thereof. The inhibitor of the present invention is an inhibitor having a structure represented by the following general formu...
|
|
WO/2023/185979A1 |
Provided are a preparation method for and use of crystalline forms of an ATX inhibitor represented by formula (I) and a salt thereof. The crystalline forms of the ATX inhibitor and the salt thereof have high oral bioavailability, low hyg...
|
|
WO/2023/191665A1 |
The invention relates, in particular, to monoclonal antibodies that specifically bind to an alpha chain of the receptor to human interleukin 4 (hIL-4Rα) and have reduced immunogenic activity as compared with an antibody dupilumab, which...
|
|
WO/2023/191384A1 |
A peptide of the present invention has the activity of inhibiting the expression of inflammatory cytokine genes, inflammatory cytokine proteins, or proteins related to inflammatory cytokine signaling in lung cells where inflammatory resp...
|
|
WO/2023/190117A1 |
The present disclosure addresses the problem of providing a method for producing a new ellagic acid-containing composition capable of improving solubility of ellagic acid. The present embodiment is a method for producing an ellagic acid-...
|
